Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $13.85M rose 24.3% year over year, ahead of the -22.8% change in trailing-twelve-month operating expenses. Sequentially, it rose 30.2% from the prior quarter. Over 3 fiscal years it compounded at +14.2% a year.

Context

  • Operating expenses amounted to 123.9% of revenue in FY2025, down 811.2 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +24.3% holds above the trailing-twelve-month pace of -22.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.85M+30.2% QoQ
Last fiscal yearDec 2025
$44.08M-37.7% YoY
LTMMar 2026
$46.79M-22.8% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.3%——
1 year-37.7%——
3-year CAGR+14.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
44.08M USD
Year-over-year change
-37.7%
4-year CAGR
+1.0%

Operating Expenses vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 operating expenses of $46.79M is the 3rd highest of the 5 companies compared; the peer median is $48.3M.
  • Its year-over-year change of -22.8% is the 3rd highest of 5, against a peer median of -22.4%.
  • Operating expenses amounts to 125.9% of revenue for VRCA, versus a peer median of 59.7%.
VRCA Competitors Peer median
Operating Expenses for VRCA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$69.54M +119.3%-2.5%—
BOLDBoundless Bio, Inc.LTM Mar 2026$59.47M -19.0%+10.3%—
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$46.79M -22.8%+14.2%125.9%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.12M -25.8%-3.3%—
QTTBQ32 Bio Inc.LTM Mar 2026$32.06M -49.4%-7.4%59.7%
Peer median (excluding VRCA) $48.3M-22.4%-2.9%59.7%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12M9.03M5.12M7.57M35.58M
Cost of Revenue472K725K746K2.74M3.44M
Gross Profit11.53M8.31M4.38M4.83M32.14M
Gross Margin96.1%92.0%85.4%63.8%90.3%
Research & Development15.93M12.2M20.3M11.84M8.86M
Selling, General & Admin26.98M17.41M47.31M58.82M35.22M
Operating Expenses42.44M29.6M70.14M70.75M44.08M
Depreciation & Amortization472K718K836K1.27M781K
EBITDA(30.31M)(21.6M)(62.2M)(65.9M)(9.36M)
EBITDA Margin-252.6%-239.1%-1213.8%-871.0%-26.3%
Operating Income(30.91M)(21.3M)(65.76M)(65.92M)(11.94M)
Operating Margin-257.6%-235.8%-1283.4%-871.3%-33.6%
Interest Income123K476K2.74M1.42M929K
Interest Expense4.3M2.17M3.96M9.41M7.74M
Other Income / Expenses(4.17M)(3.19M)(1.24M)(10.66M)(5.95M)
Income Before Tax(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Pre-Tax Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
Income Tax Expense00000
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Net Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
EPS (Basic)(12.97)(7.17)(14.78)(14.78)(1.68)
EPS (Diluted)(12.97)(7.17)(14.78)(14.78)(1.68)
Weighted Avg Shares2.7M3.42M4.53M5.18M10.65M
Weighted Avg Shares (Diluted)2.7M3.42M4.53M5.18M10.65M

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.